Johnson & Johnson has underperformed its large-cap healthcare peers and the S&P 500, with an -8% decline over the past year.
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback